{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:41:25Z","timestamp":1792554085486,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06256-9","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:02:49Z","timestamp":1785042169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series"],"prefix":"10.1186","volume":"20","author":[{"given":"Anna","family":"Witkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Killian","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padraig","family":"McGettrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Abuelmagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"6256_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/B978-0-323-75608-2.00198-1","volume-title":"Principles and practice of pediatric infectious diseases","author":"FS Huang","year":"2023","unstructured":"Huang FS, Shah SS. Ureaplasma urealyticum. In: Long SS, editor. Principles and practice of pediatric infectious diseases. 6th ed. Philadelphia: Elsevier; 2023. p. 1048\u201350.","edition":"6th ed"},{"key":"6256_CR2","unstructured":"Larru B, Zaoutis TE. Ureaplasma infections. In: Fetal and Neonatal Secrets. 3rd ed. 2014."},{"key":"6256_CR3","doi-asserted-by":"crossref","unstructured":"Jhaveri VV, Lasalvia MT. Invasive Ureaplasma Infection in Patients Receiving Rituximab and Other Humoral Immunodeficiencies. Open Forum Infect Dis. 2019;6(10):ofz399.","DOI":"10.1093\/ofid\/ofz399"},{"key":"6256_CR4","doi-asserted-by":"crossref","unstructured":"Mikulska M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document. Clin Microbiol Infect. 2018;24:S71\u2013S82.","DOI":"10.1016\/j.cmi.2018.02.003"},{"issue":"1","key":"6256_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1756285615601933","volume":"9","author":"PS Sorensen","year":"2016","unstructured":"Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9(1):44\u201352.","journal-title":"Ther Adv Neurol Disord"},{"key":"6256_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320.","journal-title":"N Engl J Med"},{"key":"6256_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"key":"6256_CR8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779\u201387.","journal-title":"Lancet"},{"issue":"5\u201306","key":"6256_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.18071\/isz.75.0163","volume":"75","author":"D Pukoli","year":"2022","unstructured":"Pukoli D, V\u00e9csei L. B-cell depletion in the therapy of multiple sclerosis. Ideggyogy Sz. 2022;75(5\u201306):163\u20139.","journal-title":"Ideggyogy Sz"},{"issue":"4","key":"6256_CR10","first-page":"491","volume":"26","author":"ET Cunningham","year":"2018","unstructured":"Cunningham ET, Flynn HW, Relhan N, Zierhut M. Endogenous Endophthalmitis. Ocul Immunol Inflamm. 2018;26(4):491\u20135.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"6256_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1086\/345667","volume":"36","author":"SC Buckingham","year":"2003","unstructured":"Buckingham SC, Crouse DT, Knapp KM, Patrick CC. Pneumonitis associated with Ureaplasma urealyticum in children with cancer. Clin Infect Dis. 2003;36(2):225\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"6256_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/1040841X.2020.1736986","volume":"46","author":"KE Sprong","year":"2020","unstructured":"Sprong KE, Mabenge M, Wright CA, Govender S. Ureaplasma species and preterm birth. Crit Rev Microbiol. 2020;46(2):169\u201381.","journal-title":"Crit Rev Microbiol"},{"key":"6256_CR13","doi-asserted-by":"crossref","unstructured":"Said El Zein, Garvey T, Amin S, Tande AJ. Native joint polyarticular septic arthritis secondary to disseminated Ureaplasma urealyticum infection. IDCases. 2023;32:e01744.","DOI":"10.1016\/j.idcr.2023.e01744"},{"key":"6256_CR14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s15010-024-02301-1","volume":"52","author":"K Oguni","year":"2024","unstructured":"Oguni K, Fukushima S, Otsuka Y, et al. Disseminated septic arthritis caused by Ureaplasma urealyticum. Infection. 2024;52:2495\u20139.","journal-title":"Infection"},{"issue":"2","key":"6256_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237916","volume":"14","author":"R Harold","year":"2021","unstructured":"Harold R, Simon GL, Akselrod H, Siegel MO, Roberts A. Ureaplasma septic polyarthritis in a young woman with neuromyelitis optica receiving rituximab. BMJ Case Rep. 2021;14(2): e237916.","journal-title":"BMJ Case Rep"},{"key":"6256_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-256029","volume":"16","author":"EE Poulsen","year":"2023","unstructured":"Poulsen EE, Jensen-Fangel S, Rudolf F. Severe Ureaplasma urealyticum infection in a patient with ocrelizumab-induced hypogammaglobulinaemia. BMJ Case Rep. 2023;16: e256029.","journal-title":"BMJ Case Rep"},{"issue":"15","key":"6256_CR17","first-page":"e1546","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(15):e1546\u201359.","journal-title":"Neurology"},{"key":"6256_CR18","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, et al. Anti-CD20 therapies in multiple sclerosis. Front Immunol. 2023;14:1004795.","journal-title":"Front Immunol"},{"issue":"9","key":"6256_CR19","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","volume":"21","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, et al. Results of a phase I\/II study of ocrelizumab. Ann Oncol. 2010;21(9):1870\u20136.","journal-title":"Ann Oncol"},{"key":"6256_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-6-1","volume":"6","author":"JD Mellor","year":"2013","unstructured":"Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"6256_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ymgme.2003.08.024","volume":"80","author":"TT Colaizy","year":"2003","unstructured":"Colaizy TT, Kuforiji T, Sklar RS, Pillers DA. PCR methods in clinical investigations of human ureaplasmas. Mol Genet Metab. 2003;80(4):389\u201397.","journal-title":"Mol Genet Metab"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06256-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:17Z","timestamp":1792552277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06256-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6256"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06256-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patients gave written informed consent to participate in the study.\u00a0Ethical approval was not required for this case series, in accordance with the institutional\/national policy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients for publication of this case series and any accompanying images. Copies of written consent are available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"648"}}